9,293 AbbVie Inc. $ABBV Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC lessened its stake in AbbVie Inc. (NYSE:ABBV) by 5.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 169,132 shares of the company’s stock after selling 9,293 shares during the quarter. AbbVie makes up approximately 0.9% of Sterling Capital Management LLC’s holdings, making the stock its 18th biggest holding. Sterling Capital Management LLC’s holdings in AbbVie were worth $44,243,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABBV. Corient Private Wealth LP acquired a new position in AbbVie in the second quarter worth about $559,736,000. Legal & General Group Plc acquired a new stake in AbbVie during the second quarter valued at approximately $2,905,952,000. Jupiter Topco LLC acquired a new stake in AbbVie during the second quarter valued at approximately $1,560,354,000. Diamant Asset Management Inc. raised its stake in AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after buying an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in AbbVie during the 2nd quarter worth approximately $817,473,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.2%

Shares of NYSE:ABBV opened at $285.66 on Friday. The company has a market cap of $504.70 billion, a PE ratio of 80.69, a P/E/G ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40. The firm has a 50-day simple moving average of $266.33 and a 200 day simple moving average of $241.77.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the company posted $2.97 earnings per share. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts forecast that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and raised their price objective for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Finally, Guggenheim restated a “buy” rating and set a $288.00 price objective on shares of AbbVie in a research note on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $279.86.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.